


AMENDMENTS TO THE CLAIMS:




Amend the claims as follows:

1. (Currently Amended) A biphenyl compound ~~Biphenyl compounds~~ substituted with an aromatic or heteroaromatic radical, characterized in that they correspond to the general formula (I) below:



in which:

Ar represents an aromatic or heteroaromatic radical chosen from:



Z being O or S,

R₁ represents ~~CH₃, CH₂-OH, OR₈ or -COR₉,~~

~~—R₂ and R₃, which may be identical or different, represent H, linear or branched C₄-C₄₅ alkyl, cycloalkyl, ZR₁₀ or a polyether radical, at least one from among R₂ and R₃ representing a linear or branched C₄-C₄₅ alkyl radical, or~~

R₂ and R₃, taken together, form a 5- or 6- membered ring, optionally substituted with at least one methyl and/or optionally interrupted by an oxygen or sulphur atom or by an SO or SO₂ radical,

R₄ represents H, a halogen atom, linear or branched C₁-C₂₀ alkyl, -OR₁₀, -OCOR₁₁ or a polyether radical,

R₅ represents H, a halogen atom, linear or branched C₁-C₂₀ alkyl,

-OCOR₁₁, -OR₁₂, mono- or polyhydroxyalkyl, -NO₂,
 $\text{---}(\text{CH}_2)_n\text{---N}\begin{matrix} \nearrow \text{r} \\ \searrow \text{r}' \end{matrix}$,
 -(CH₂)_n-NHCOCH₃, -CH=CH-COR₁₃, -(CH₂)_nCOR₁₃, n being 0 to 6, -O-(CH₂)_mCOR₁₃,
 -O-(CH₂)_mOH, m being 1 to 12, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, a polyether radical or a -CH₂- polyether radical,

R₆ represents H, lower alkyl or -OR₁₀,

R₇ represents H, a halogen atom, linear or branched C₁-C₂₀ alkyl, -OR₁₀ or -OCOR₁₁ or a polyether radical,

~~_____ R₈ represents H, lower alkyl, -COR₁₄~~

R₉ represents [[H, lower alkyl,] -OR₁₄ [[or $\text{---N}\begin{matrix} \nearrow \text{r} \\ \searrow \text{r}' \end{matrix}$]],

R₁₀ represents H or lower alkyl,

R₁₁ represents lower alkyl,

R₁₂ represents H, linear or branched C₁-C₂₀ alkyl, mono- or polyhydroxyalkyl, or optionally substituted aryl or aralkyl,

R₁₃ represents H, lower alkyl, -OR₁₀, aryl or $\text{---N}\begin{matrix} \nearrow \text{r} \\ \searrow \text{r}' \end{matrix}$,

R_{14} represents H, ~~alkyl, linear or branched C_4 - C_{20} alkyl, alkenyl, mono- or polyhydroxyalkyl, optionally substituted aryl or aralkyl, or a sugar residue,~~

r' and r'' , which may be identical or different, represent H, OH, lower alkyl, mono- or polyhydroxyalkyl, optionally substituted aryl, an amino acid residue or a peptide residue, or r' and r'' , taken together, form a heterocycle,

or a salt and the salts of the compound ~~compounds~~ of formula (I) when R_4 represents a carboxylic acid function, as well as the or an optical or and geometrical isomer isomers of the compound ~~said compounds~~ of formula (I).

2. (Currently Amended) A compound ~~Compounds~~ according to Claim 1, characterized in that they are in the form of a salt of an alkali metal or alkaline-earth metal, or alternatively of zinc or of an organic amine.

3. (Currently Amended) A compound ~~Compounds~~ according to ~~either of~~ Claim 1, characterized in that the lower alkyl radical is chosen from the group consisting of the methyl, ethyl, isopropyl, butyl, tert-butyl and hexyl radicals.

4. (Currently Amended) A compound ~~Compounds~~ according to Claim 1, characterized in that the linear or branched alkyl radical, when it is C_1 - C_{15} , is chosen from the group consisting of the methyl, ethyl, propyl, 2-ethylhexyl, octyl and dodecyl radicals, and, when it is C_1 - C_{20} , is also chosen from the hexadecyl and octadecyl radicals.

5. (Currently Amended) A compound ~~Compounds~~ according to Claim 1, characterized in that the monohydroxyalkyl radical is chosen from the group consisting of the hydroxymethyl, 2-hydroxyethyl, 2-hydroxypropyl and 3-hydroxypropyl radicals.

6. (Currently Amended) A compound ~~Compounds~~ according to Claim 1, characterized in that the polyhydroxyalkyl radical is chosen from the group consisting of the 2,3-dihydroxypropyl, 2,3, 4-trihydroxybutyl and 2,3,4,5-tetrahydroxypentyl radicals and the pentaerythritol residue.

7. (Currently Amended) A compound ~~Compounds~~ according to Claim 1, characterized in that the polyether radical is chosen from the group consisting of the methoxymethoxy, methoxyethoxy and methoxyethoxymethoxy radicals.

8. (Currently Amended) A compound ~~Compounds~~ according to Claim 1, characterized in that the -CH₂-polyether radical is chosen from the group consisting of the methoxymethoxymethyl, ethoxymethoxymethyl and methoxyethoxymethoxymethyl radicals.

9. (Currently Amended) A compound ~~Compounds~~ according to Claim 1, characterized in that the aryl radical is a phenyl radical optionally substituted with at least one halogen, a hydroxyl, a nitro function, a polyether radical or an amino function optionally protected with an acetyl group or optionally substituted with at least one C₁-C₆ lower alkyl or alkoxy.

10. (Currently Amended) A compound ~~Compounds~~ according to Claim 1, characterized in that the aralkyl radical is chosen from the group consisting of benzyl and phenethyl radicals optionally substituted with at least one halogen atom, a hydroxyl, a nitro function, a polyether radical or an amino function optionally protected with an acetyl group or optionally substituted with at least one C₁-C₆ lower alkyl or alkoxy.

11. (Currently Amended) A compound ~~Compounds~~ according to Claim 1, characterized in that the heteroaryl radical is chosen from the group consisting of

pyridyl, furyl and thienyl radicals, optionally substituted with at least one halogen, a lower alkyl, a hydroxyl, a C₁-C₃ alkoxy, a nitro function, a polyether radical or an amino function optionally protected with an acetyl group or optionally substituted with at least one C₁-C₆ lower alkyl or alkoxy.

Claims 12-13. (Cancelled)


14. (Currently Amended) A compound ~~Compounds~~ according to Claim 1, characterized in that the amino acid residue is chosen from the group consisting of residues derived from lysine, from glycine ~~or~~ and from aspartic acid.

15. (Currently Amended) A compound ~~Compounds~~ according to Claim 1, characterized in that the peptide residue is chosen from the group consisting of dipeptide and tripeptide residues.

16. (Currently Amended) A compound ~~Compounds~~ according to Claim 1, characterized in that when r' and r'' form a heterocycle, this is chosen from the group consisting of piperidino, morpholino, pyrrolidino and piperazino radicals, optionally substituted in position 4 with a C₁-C₆ alkyl or a mono- or polyhydroxyalkyl.


17. (Currently Amended) A compound ~~Compounds~~ according to Claim 1, characterized in that the halogen atom is chosen from the group consisting of fluorine, chlorine and bromine.

18. (Currently Amended) A compound ~~Compounds~~ according to Claim 1, characterized in that they correspond to the general formulae (II) ~~and (III)~~ below:



in which:

Ar represents a radical of formula (a) or (b) below:



R₁, R₄, R₅, R₆, and R₇ [[and Z]] having the same meanings as those given in

Claim 1,

R₁₅, R₁₆, R₁₇ and R₁₈, which may be identical or different, represent H or -CH₃,

and

t is 1 or 2.

19. (Currently Amended) A compound ~~Compounds~~ according to Claim 1,
 characterized in that they are taken from the group consisting of:

~~4-[4-hydroxy-3-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenyl]benzoic acid, and its methyl ester,~~

~~4-[4-(5-hydroxypentyl)oxy-3-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenyl]benzoic acid, and its methyl ester,~~

~~-4-[4-(6-hydroxyhexyloxy)-3-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenyl]benzoic acid, and its methyl ester,~~

~~-4-[4-(7-hydroxyheptyloxy)-3-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenyl]benzoic acid,~~

~~-4-[4-(8-hydroxyoctyloxy)-3-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenyl]benzoic acid,~~

~~-4-[4-(9-hydroxynonyloxy)-3-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenyl]benzoic acid,~~

~~-4-[4-methoxy-3-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenyl]benzoic acid,~~

~~-4-[4-methoxyethoxymethoxy-3-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenyl]benzoic acid,~~

~~-4-[4-benzyloxy-3-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenyl]benzoic acid,~~

~~-4'-(2,3-dihydroxypropoxy)-3'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-carboxylic acid (racemic),~~

~~-4'-(2,2-dimethyl[1,3]dioxolan-4-ylmethoxy)-3'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-carboxylic acid (racemic),~~

~~-4'-(2-morpholin-4-yl-ethoxy)-3'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-carboxylic acid,~~

~~-methyl-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-[1,1';4',1'']terphenyl-4"-carboxylate,~~

~~-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-[1,1';4',1'']terphenyl-4''~~
carboxylic acid,
~~-4-methoxymethoxy-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-~~
~~[1,1';4',1'']terphenyl-4''~~ carboxylic acid,
~~-4-hydroxy-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-~~
~~[1,1';4',1'']terphenyl-4''~~ carboxylic acid,
~~-4-methoxy-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-~~
~~[1,1';4',1'']terphenyl-4''~~ carboxylic acid,
~~-3-methoxymethoxy-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-~~
~~[1,1';4',1'']terphenyl-4''~~ carboxylic acid,
~~-3-hydroxy-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-~~
~~[1,1';4',1'']terphenyl-4''~~ carboxylic acid,
~~-3-methoxy-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-~~
~~[1,1';4',1'']terphenyl-4''~~ carboxylic acid,
~~-2-methoxymethoxy-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-~~
~~[1,1';4',1'']terphenyl-4''~~ carboxylic acid,
~~-2-hydroxy-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-~~
~~[1,1';4',1'']terphenyl-4''~~ carboxylic acid,
~~-2-methoxy-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-~~
~~[1,1';4',1'']terphenyl-4''~~ carboxylic acid,
~~-2-methoxymethoxy-5'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-~~
naphthyl)biphenyl-4-carboxylic acid,

~~-2'-methoxy-5'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-~~
carboxylic acid,

~~-2'-propyloxy-5'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-~~
carboxylic acid,

~~-2'-hydroxy-5'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-~~
carboxylic acid,

~~-4'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-[1,1';2',1'']terphenyl-4''-~~
carboxylic acid,

~~-2'-methoxymethoxy-3'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-~~
biphenyl-4'-carboxylic acid,

~~-2'-hydroxy-3'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-~~
carboxylic acid,

~~-2'-methoxy-3'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-~~
carboxylic acid,

~~-3'-methoxymethoxymethyl-5'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-~~
naphthyl)biphenyl-4-carboxylic acid,

~~-3'-hydroxymethyl-5'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-~~
4-carboxylic acid,

~~-2'-(4,4-dimethylthiochroman-7-yl)-[1,1';4',1'']terphenyl-4''-carboxylic acid,~~

~~-2'-(4,4-dimethylthiochroman-6-yl)-[1,1';4',1'']terphenyl-4''-carboxylic acid,~~

~~-2'-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-[1,1';4',1'']terphenyl-4''-~~
carboxylic acid,

~~-2'-(3-methoxymethoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-~~
~~[1,1';4',1'']terphenyl-4''-carboxylic acid,~~

~~-2'-(3-hydroxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-~~
~~[1,1';4',1'']terphenyl-4''-carboxylic acid,~~

~~-2'-(3-methoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-~~
~~[1,1';4',1'']terphenyl-4''-carboxylic acid,~~

~~-2'-(3-propyloxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-~~
~~[1,1';4',1'']terphenyl-4''-carboxylic acid,~~

~~-3''-methyl-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-~~
~~[1,1';4',1'']terphenyl-4''-carboxylic acid,~~

~~-2''-hydroxy-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-~~
~~[1,1';4',1'']terphenyl-4''-carboxylic acid,~~

~~-2''-methoxymethoxy-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-~~
~~[1,1';4',1'']terphenyl-4''-carboxylic acid,~~

~~-2''-methoxy-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-~~
~~[1,1';4',1'']terphenyl-4''-carboxylic acid,~~

~~-2''-propyloxy-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-~~
~~[1,1';4',1'']terphenyl-4''-carboxylic acid,~~

~~-3''-hydroxy-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-~~
~~[1,1';4',1'']terphenyl-4''-carboxylic acid,~~

- 6-[2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-yl]nicotinic
acid, and

- 5-[2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-yl]2-pyridinecarboxylic acid,
~~-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-[1,1';4',1'']terphenyl-4''~~
hydroxamic acid,
~~-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-[1,1';4',1'']terphenyl-4''~~ ol,
~~-[2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-[1,1';4',1'']terphenyl-4''~~
yl]methanol,
~~-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-[1,1';4',1'']terphenyl-4''~~
carbaldehyde,
~~-4'-methoxycarbonylmethoxy-3'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-~~
naphthyl)biphenyl-4-carboxylic acid,
~~-4'-carboxymethoxy-3'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-~~
naphthyl)biphenyl-4-carboxylic acid,
~~-4'-(5-ethoxycarbonylpentyloxy)-3'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-~~
naphthyl)biphenyl-4-carboxylic acid,
~~-4'-(5-carboxypentyloxy)-3'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-~~
naphthyl)biphenyl-4-carboxylic acid,
~~-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-[1,1';4',1'']terphenyl-4''~~
carboxamide,
~~-N-ethyl-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-~~
[1,1';4',1'']terphenyl-4'' carboxamide,
~~-N,N-diethyl-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-~~
[1,1';4',1'']terphenyl-4'' carboxamide,

~~—morpholin-4-yl-[2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-~~
~~[1,1';4',1'']terphenyl-4''-yl]methanone,~~

~~—(4-hydroxyphenyl)-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-~~
~~[1,1';4',1'']terphenyl-4''-carboxamide,~~

~~—3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-carboxymethyl-~~
~~4'-carboxylic acid,~~

~~—3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4,4'-dicarboxylic~~
~~acid,~~

~~—3'-methoxymethoxy-5'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-~~
~~naphthyl)biphenyl-4-carboxylic acid,~~

~~—3'-methoxy-5'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-~~
~~carboxylic acid,~~

~~—3'-propyloxy-5'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-~~
~~carboxylic acid,~~

~~—3'-hydroxy-5'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-~~
~~carboxylic acid,~~

~~—4'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-[1,1';3',1'']terphenyl-4''-~~
~~carboxylic acid,~~

~~—4'-(5-carboxamidopentyloxy)-3'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-~~
~~naphthyl)biphenyl-4-carboxylic acid,~~

~~—3'-methoxycarbonyl-5'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-~~
~~naphthyl)biphenyl-4-carboxylic acid,~~

~~-3'-carboxyl-5'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-~~
~~carboxylic acid,~~

~~-2'-(4-hydroxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-~~
~~[1,1';4',1'']terphenyl-4''-carboxylic acid,~~

~~-2'-(4-methoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-~~
~~[1,1';4',1'']terphenyl-4''-carboxylic acid,~~

~~-2'-(4-propyloxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-~~
~~[1,1';4',1'']terphenyl-4''-carboxylic acid,~~

~~-2'-(4-methoxymethoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-~~
~~[1,1';4',1'']terphenyl-4''-carboxylic acid,~~

~~-2-[2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)biphenyl-4-yl]-4-~~
~~thiophenecarboxylic acid.~~

20. (Previously Presented) A compound ~~Compounds~~ according to Claim 1, for use as a medicinal product.

Claims 21-22. (Cancelled)

23. (Currently Amended) A pharmaceutical ~~Pharmaceutical~~ composition, characterized in that it comprises, in a pharmaceutically acceptable support, at least one compound as defined according to Claim 1.

24. (Currently Amended) A pharmaceutical composition ~~Composition~~-according to Claim 23, characterized in that the concentration of said at least one compound is between 0.001% and 5% by weight relative to the total weight of the composition.

25. (Currently Amended) A cosmetic ~~Cosmetic~~-composition, characterized in that it contains, in a cosmetically acceptable support, at least one compound as defined according to Claim 1.

26. (Currently Amended) A cosmetic composition ~~Composition~~-according to Claim 25, characterized in that the concentration of said at least one compound is between 0.001 and 3% by weight relative to the total weight of the composition.

Claim 27. (Cancelled)

28. (Previously Presented) A dermatological, immunoallergic, cardiovascular and/or ophthalmological treatment method comprising administering a composition comprising a compound according to Claim 1 to a person in need of said treatment.

29. (new) A cosmetic treatment method for repairing or combating aging of the skin comprising applying to the part of the skin to be treated a composition comprising a compound according to claim 1 to a person in need of said cosmetic treatment.

30. (new) A dermatological, immunoallergic, cardiovascular or ophthalmological treatment method comprising administering a composition comprising a compound according to claim 1, to a person in need of said treatment.

31. (new) The method of claim 29, for treating dermatological complaints associated with keratinization disorders.

32. (new) The method of claim 29, for treating acne.

33. (new) The method of claim 29, for treating ichthyosis, Darier's diseases, palmoplantar keratoderma, leucophasia and cutaneous or mucous lichen.

34. (new) The method of claim 29, for treating psoriasis, cutaneous atopy, respiratory atopy or gingival hypertrophy.

35. (new) The method of claim 34, for treating eczema.

36. (new) The method of claim 29, for treating dermal or epiderman proliferations.

37. (new) The method of claim 36, for treating warts, papillomatoses and uv-induced proliferations.

38. (new) The method of claim 30, for treating bullosis or collagen diseases.

39. (new) The method of claim 30, for treating corneopathies.

40. (new) The method of claim 30, for treating cutaneous atrophy.

41. (new) The method of claim 30, for combating cicatrization disorders or stretch marks.

42. (new) The method of claim 30, for combating seborrhoea.

43. (new) The method of claim 30, for combating arthritis.

44. (new) The method of claim 30, for combating alopecia.

45. (new) The method of claim 30, for combating arteriosclerosis.